What are the recommended doses of capecitabine and oxaliplatin in the CAPOX (capecitabine plus oxaliplatin) adjuvant regimen, including adjustments for renal impairment?

CAPOX Dosing Regimen

The standard CAPOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 and capecitabine 1,000 mg/m² orally twice daily on days 1-14, repeated every 3 weeks for 8 cycles (6 months total duration) in the adjuvant setting. 1

Standard Dosing

Oxaliplatin Component

• Dose: 130 mg/m² IV infusion over 2 hours on day 1
• Cycle frequency: Every 3 weeks 1, 2

Capecitabine Component

• Dose: 1,000 mg/m² orally twice daily (total daily dose: 2,000 mg/m²)
• Schedule: Days 1-14 of each 3-week cycle
• Duration: 8 cycles for adjuvant therapy 1

Critical Dosing Considerations

Geographic Variation in Starting Dose

Important caveat: The capecitabine dose requires careful consideration based on patient population. European trials established 1,000 mg/m² twice daily as standard, but North American patients experience greater fluoropyrimidine toxicity 2, 3. The evidence shows a range of 850-1,000 mg/m² twice daily is acceptable 2, with some guidelines citing 850-1,250 mg/m² 2.

For good performance status patients, start at 1,000 mg/m² twice daily with close monitoring during the first cycle for toxicity and adjust as needed 2.

Renal Impairment Adjustments

Capecitabine Dose Modifications

Patients with diminished creatinine clearance require dose modification 2. The FDA label and clinical evidence demonstrate:

• CrCl >50 mL/min: No dose adjustment needed
• CrCl 30-50 mL/min: Reduce capecitabine dose (specific reduction not standardized but monitoring essential)
• CrCl <30 mL/min: Capecitabine is contraindicated or requires substantial reduction 4, 5

Oxaliplatin Dose Modifications

• CrCl >50 mL/min: Standard dose of 130 mg/m² (or 85 mg/m² for mFOLFOX6)
• CrCl 30-49 mL/min: No dose reduction required, but monitor closely 6
• CrCl <30 mL/min: Reduce to 65 mg/m² 6

Critical point: Patients with borderline renal function (CrCl 50-60 mL/min) are at significantly higher risk for toxicity and early discontinuation 4, 5. In elderly patients with CrCl <50 mL/min, the discontinuation rate within 4 cycles was 21.1% versus 2.9% in those with normal renal function 4.

Duration and Cycle Modifications

Standard Duration

• Total duration: 6 months (8 cycles of 3 weeks each) 1

Shortened Duration Option

Based on the IDEA study results, high-risk stage II and low-risk stage III patients (T1-3N1) may consider 3 months of CAPOX (4 cycles) instead of 6 months 1.

Oxaliplatin Discontinuation Strategy

Strongly consider discontinuing oxaliplatin after 3-4 months of therapy (or sooner if grade ≥2 neurotoxicity develops) while maintaining fluoropyrimidine until tumor progression 2, 7, 2. Oxaliplatin may be reintroduced if previously discontinued for neurotoxicity rather than disease progression.

Common Pitfalls

1. Standardized creatinine impact: Modern enzymatic creatinine measurements may underestimate renal impairment. Consider adding 0.2 mg/dL to serum creatinine when calculating CrCl using Cockcroft-Gault equation for patients with borderline function 5.

2. Female patients: Only 34.6% of female patients completed all planned cycles in real-world data, compared to higher rates in males, suggesting need for closer monitoring and earlier supportive interventions 8.

3. Real-world completion rates: Only 44.4% of patients complete all planned CAPOX cycles, with completion rates of 55% for 4 cycles versus 33% for 8 cycles 8. This underscores the importance of aggressive supportive care from cycle 1.

4. Elderly patients with renal impairment: This population has markedly decreased tolerability, with 42.3% experiencing grade 3 adverse events versus 31.3% in those with normal renal function 4.